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Abstract 
Background: Evidence is accumulating to link cancer stem cells to the pathogenesis and progression of osteosar-
coma. The aim of this study is to investigate the role of miR-335 in osteosarcoma stem cells.
Methods: Tumor spheroid culture and flow cytometry were applied to screen out osteosarcoma stem cells. Real-
time quantitative PCR was used to detect the expression level of miR-335 in MG63, U2OS and 143B osteosarcoma 
stem cells. The relationship of miR-335 expression with osteosarcoma stem cells was then analyzed. Transwell assay 
and transplantation assay were performed to elucidate biological effects of miR-335 on cell invasion and vivo tumor 
formation. Western Blot and luciferase assays were executed to investigate the regulation of POU5F1 by miR-335.
Results: The expression of miR-335 in osteosarcoma stem cells was lower than their differentiated counterparts. Cells 
expressing miR-335 possessed decreased stem cell-like properties. Gain or loss of function assays were applied to 
find that miR-335 antagonist promoted stem cell-like properties as well as invasion. Luciferase report and transfection 
assay showed that POU5F1 was downregulated by miR-335. Pre-miR-335 resulted in tumor enhanced sensitivity to 
traditional chemotherapy, whereas anti-miR-335 promoted chemoresistance. Finally, the inhibitory effect of miR-335 
on in vivo tumor formation showed that combination of pre-miR-335 with cisplatin further reduced the tumor size, 
and miR-335 brought down the sphere formation capacity induced by cisplatin.
Conclusions: The current study demonstrates that miR-335 negatively regulates osteosarcoma stem cell-like proper-
ties by targeting POU5F1, and miR-335 could target CSCs to synergize with traditional chemotherapeutic agents to 
overcome osteosarcoma.
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Background
Osteosarcoma cells are highly aggressive and are widely 
recognized as the most common primary malignant bone 
tumor in adolescents [1]. Traditional chemotherapy is 
associated with systematic toxicity and is less selective, 
and approximately 10–25% of patients respond poorly 
to the current chemotherapy [2]. Therefore, effective tar-
geted therapy of osteosarcoma is an urgent problem.
Cancer stem cells (CSCs) are defined as cells with a 
self-renewal ability that can generate heterogeneous 
cancer cells, which play a key role in recurrence, metas-
tasis, and drug resistance [3]. Several studies have also 
confirmed the existence of osteosarcoma stem cells. 
Gibbs first reported that stem-like cells exist in osteo-
sarcoma, which are capable of forming self-renewable 
tumor spheres. Honoki reported that ALDH1 in MG63 
sarcospheres was significantly higher and that these 
cells were involved in multidrug resistance [4]. Adhi-
kari et  al. have identified mouse and human osteosar-
coma stem cells using mesenchymal stem cell markers 
CD-117 and Stro-1. These markers were preferentially 
expressed in spheres and doxorubicin-resistant cells 
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[5]. The concept of CSCs provides a theoretical basis 
for specific targeted therapy. Therefore, studies of the 
regulation of osteosarcoma stem cells are especially 
important.
miRNAs are short non-coding RNAs that regulate dif-
ferent aspects of post-transcriptional gene expression, 
miRNAs usually bind to the 3′-untranslated region (3′-
UTR) of targeted mRNAs, to cause translational degrada-
tion or target repression and gene silencing [6]. Recently, 
increasing evidence has suggested that miR-335 plays a 
role in the regulation of cancer progression. For instance, 
miR-335 was reported to inhibit small cell lung cancer 
bone metastases via the IGF-IR and RANKL pathway [7]. 
It has also been reported that miR-335 targets Bcl-w as 
an invasion suppressor gene in ovarian cancer [8]. Heyn 
[9] reported that miR-335 is crucial for the BRCA1 regu-
latory cascade in breast cancer development. In osteo-
sarcoma, it has been suggested that miR-335 suppresses 
tumors by regulating the ROCK1 gene [10]. However, the 
relationship between miR-335 and osteosarcoma stem 
cells remains unclear.
In the present study, we showed that the levels of miR-
335 were downregulated in osteosarcoma stem cells. 
Moreover, cells expressing miR-335 possessed decreased 
stem cell-like properties. These effects were partially 
caused by regulation of miR-335 targeting POU5F1. Fur-
thermore, we demonstrated that miR-335 increased che-
mosensitivity and inhibited in  vivo tumor formation by 
targeting osteosarcoma stem cells.
Methods
Cell lines and cell culture
MG63, U2OS and 143B cells were purchased from China 
Center for Type Culture Collection (CCTCC). HEK293 
cells were obtained from Shanghai Institute for Biologi-
cal Sciences of the Chinese Academy of Sciences. All the 
cells were cultured in RPMI-1640 containing 10% FBS 
and 1% penicillin/streptomycin. Cells were propagated at 
37 °C with 5% CO2 and 100% humidity. Cell viability was 
determined using trypan blue staining.
Tumor spheroid culture
Cells were plated in six-well ultralow attachment plates 
(Corning) at a density of 5000 cells/well in RPMI-1640 
supplemented with B27 Supplement (Invitrogen), 10 ng/
mL human EGF (Sigma-Aldrich), and 10 ng/mL human 
bFGF (Sigma-Aldrich). Cells were incubated at 37  °C in 
a humidified atmosphere of 95% air and 5% CO2. Fresh 
aliquots of EGF and bFGF were added every other day. 
After culture for 2 weeks, colonies larger than 50 μm in 
size were regarded as sarcospheres and quantitated by 
inverted phase contrast microscopy.
Flow cytometry
For analysis of cell surface markers, osteosarcoma cells 
were harvested and resuspended in PBS/0.5% normal 
rabbit serum (Sigma-Aldrich), and blocked on ice for 
15  min. Cells were subsequently labelled with Alexa 
Fluor® 647 anti-human Stro-1 antibody (BioLegend) and 
PE anti-human CD117 (c-kit) antibody (BioLegend) for 
60 min and maintained on ice until analysis. The expres-
sion was assessed by flow cytometry and data were ana-
lyzed. The double positive (DP) and double negative 
(DN) cells were then sorted and collected using a Bec-
ton–Dickinson FACSort (San Jose).
In order to divide the cells into different subpopulations 
according to their miR-335 expression status, we incu-
bated the cells with miR-335-5p Hu-Cy5 SmartFlare™ 
RNA Detection Probe (Millipore), overnight for 16  h. 
The fluorescence was then detected and cells were sorted 
into miR-335-high and miR-335-low subpopulation using 
a Becton–Dickinson FACSort (San Jose). The collected 
cells were then send for subsequent experiments.
Luciferase assays
Basing upon the pMIR-REPORT vector the luciferase 
reporter was constructed (Ambion). Strands of the oligo-
nucleotides of the POU5F1-3′-UTR containing the miR-
335 binding site were subcloned into the pMIR-REPORT 
vector after being synthesized and annealed. Scrambled 
sequences were also subcloned into the same vector act-
ing as negative control. The POU5F1-3′-UTR-miR-335 
or control plasmid was transfected into the HEK293 cells 
using Lipofectamine 2000 (Invitrogen). Luminescence 
were assayed using the luminometer.
Transfection assay
Anti-miR-335 and pre-miR-335 used in this study were 
synthesized and confirmed by Shanghai Sangon Biotech 
Co. Ltd. Scrambled RNA (100 nmol) was act as negative 
control. We transfected the pre-miR-335, anti-miR-335 
and their negative controls into all three cell lines in 
6-well plates (1  ×  105 cell per well) with 5  μL siPORT 
NeoFX transfection agent (Ambion) according to the 
manufacturer’s instructions. The cells were harvested for 
further experiments at the indicated time.
Transwell assay
To test the cell invasion capability, we precoated 8 micron 
transwells with 10 μg/cm2 matrigel (BD Bioscience), then 
added 3 × 106 cells into the upper chamber with serum-
free medium. The medium containing 10% FBS was put 
into the lower chamber as chemo-attractant. Cells were 
allowed to invade for 24  h incubation. Remaining cells 
which did not invade through the pores were carefully 
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wiped out. Matrigel membranes were fixed in 90% meth-
anol and then stained with crystal violet solution. Five 
random fields were counted by an inverted microscope 
(Olympus) examination. Each experiment was repeated 
at least three times.
qRT‑PCR
Total RNAs including mRNAs and small RNA fraction 
were isolated from cells using TRIZOL reagent (Invit-
rogen), and reverse transcriptions were performed by 
Takara RNA PCR kit (Takara) according to the manu-
facturer’s instructions. Real-time PCR was performed 
using a SYBR Green detection system which the U6 small 
nuclear RNA and β-actin mRNA were used as internal 
controls. All the reactions were repeated in three times. 
Forward and reverse primers for miR-335 and U6 were 
5′-TCAAGAGCAATAACGAAAAATGT-3′, 5′-GCTGT 
CAACGATACGCTACGT-3′; and 5′-CGCTTCGGCA 
GCACATATAC-3′, 5′-TTCACGAATTTGCGTGTCAT-3′; 
respectively. The primers for POU5F1 and β-actin mRNA 
were 5′-GAGTGAGAGGCAACCTGGAGAAT-3′, 5′-AC 




Total proteins from transfected cells were obtained 
according to the manufacturer’s instructions (Sigma). We 
resolved the proteins by 10% SDS-PAGE gel and trans-
ferred them onto the PVDF membrane (Millipore). After 
being blocked in 10% nonfat dried milk for 2 h, the blots 
were incubated with anti-POU5F1 (1:1000; TA324014, 
OriGene) or anti-Sox2 (1:700; TA321559, OriGene) at 
4  °C overnight. After washing three times with TBST, 
the blots were incubated with secondary antibody at 
room temperature for 1 h. After washing three times with 
TBST, membranes were developed by using enhanced 
chemiluminescence. β-actin served as an endogenous 
control.
Cell cytotoxicity assay
The cells in each well containing 100  μL medium were 
incubated with 10 μL cell counting kit-8 (CCK-8) at 37 °C 
for 2  h. The optical density (OD) of each well was then 
measured at 450 nm using a microplate reader.
Animals and transplantation assay
To determine the in  vivo tumorigenicity, BALB/C nude 
mice about 6 weeks old were purchased and maintained 
at the Center for Animal Experiment at Renmin Hospi-
tal of Wuhan University. Osteosarcoma cells (1  ×  106) 
transfected with the pre-miR-335 or vehicle construct 
were counted by trypan blue staining, and suspended 
in 10 μL of 50% Matrigel/PBS. The mice were randomly 
divided into four groups (Vehicle, Cisplatin, pre-miR-335 
and cisplatin  +  pre-miR-335 group), with six mice in 
each group. For cisplatin treatment, the mice received 
subcutaneous injection of 5 mg/kg cisplatin per week for 
6 weeks. Due to the transient effect of pre-miR-335 trans-
fection, the mice received intratumoral injection with 
4  μg of lipofectamine 2000-encapsulated pre-miR-335 
every week for the last 4 weeks. Tumors were monitored 
as long as 6 weeks. Data were accumulated from at least 
three independent experiments.
Statistical analysis
All data were expressed as the mean ±  standard devia-
tion (SD). Statistical analysis were made between two 
groups with the t test. One-way ANOVA followed by 
multiple comparisons among the means was used where 
more than three means were compared. P  <  0.05 was 
considered as statistically significant.
Results
Expression of miR‑335 is downregulated in osteosarcoma 
stem cells
Because CD117 and Stro-1 double positive cells are 
thought to be enriched for osteosarcoma CSCs, we then 
compared miR-335 expression in double positive (DP) 
and double negative (DN) cell populations, and showed 
that the expression of miR-335 decreased significantly 
in DP cells in all three cell lines (Fig. 1a). CSCs are capa-
ble of forming spheres when cultured without serum 
and in an anchorage-independent manner, so we exam-
ined miR-335 expression in cells cultured under sphere-
forming conditions. There was a significant decrease in 
the expression of miR-335 in sphere-cultured MG63 and 
143B cells compared with their monolayer counterparts. 
This trend was also observed in U2OS cells although 
without statistical significance (Fig.  1b). Our previous 
study confirmed the selection of osteosarcoma CSCs by 
short-term cisplatin exposure [11]. In the present study, 
we further showed that the expression of miR-335 was 
significantly lower in resistant cells compared with con-
trol cells (Fig.  1c). Together, these results showed that 
miR-335 expression affected growth of osteosarcoma 
CSCs.
Cells expressing miR‑335 showed decreased stem cell‑like 
properties
Based on the aforementioned results, we separated 
three osteosarcoma cell lines into miR-335-high and 
miR-335-low in order to compare their stem cell-like 
properties (Fig. 1d). CD117 and Stro-1 have been linked 
to cancer stem cells in osteosarcoma, so we determined 
whether miR-335-low cells were enriched with cells 
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expressing these markers. The CD117 and Stro-1 double 
positive rate for MG63, U2OS and 143B miR-335-low 
cells were significantly higher than the miR-335-high 
cells (Fig.  1e, f ). CSCs possess a transcriptional profile 
similar to that of embryonic stem cells [12]. The expres-
sion of the genes POU5F1 and Sox2, were significantly 
downregulated in miR-335-high cells compared with 
miR-335-low cells (Fig.  1g). Spheroid formation has 
been widely used to assess the in  vitro self-renewal 
potential of stem cell-like cells, so we compared the 
ability of miR-335-low and miR-335-high cells to form 
sarcospheres. The miR-335-low cells formed more sar-
cospheres than miR-335-high cells in all three osteo-
sarcoma cell lines (Fig. 1h). These results suggested that 
miR-335 negatively correlated with osteosarcoma stem 
cell-like properties.
Downregulation of miR‑335 enhanced osteosarcoma stem 
cell‑like characteristics
To confirm the effect of miR-335 on the stem cell-like 
properties of osteosarcoma cells, all three cell lines were 
transfected with pre-miR-335, anti-miR-335, or their 
negative controls respectively. The DP ratios of both 
CD117/Stro-1 and sarcosphere formation were signifi-
cantly increased when exposed to a miR-335 antago-
nist, whereas pre-miR-335 inhibited the DP ratio and 
sarcosphere formation efficiency when compared with 
negative controls (Fig. 2a, b). CSCs are closely related to 
invasion and metastasis, so we determined the effect of 
miR-335 on cell invasion. The Transwell invasion assay 
showed that anti-miR-335 treatment of all three cell lines 
increased invasion of osteosarcoma cells when compared 
to negative controls, while pre-miR-335 inhibited cell 
Fig. 1 miR-335 was associated with osteosarcoma stem cells. a The relative expression of miR-335 were determined by qRT-PCR in CD117 and 
Stro-1 double positive (DP) cells and double negative (DN) cells. b miR-335 relative expression in sphere and monolayer culture conditions were 
examined. c The relative expression of miR-335 in the cisplatin resistant and control cells were tested. d The cells were divided into two groups 
according to their expression of miR-335. e A representative flow cytometric analyses of CD117+/Sro-1+ expression among miR-335-high and miR-
335-low cells. f CD117+/Sro-1+ DP ratio in miR-335-low group was generally higher compared with miR-335-high in all three cell line. g Western-
Blotting assay showed that POU5F1 and Sox2 expression were significantly decreased in miR-335-high compared with miR-335-low cells. h The 
ability to form sarcospheres was higher in miR-335-low compared with miR-335-high cells. All experiments were carried out at least triplicates and 
the data were presented as the mean ± SD. Student t test was performed to evaluate the difference. *P < 0.05; **P < 0.01
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invasion (Fig.  2c). Taken together, the results suggested 
that miR-335 was a suppressor of osteosarcoma stem 
cells.
miR‑335 negatively regulated POU5F1 gene expression
Using Target Scan tools to search the target gene for 
miR-335, the POU5F1 3′-UTR was found to contain a 
putative target sequence for miR-335 (Fig.  3a). To fur-
ther confirm if miR-335 binds directly to the 3′UTR of 
POU5F1, a pMIRREPORT Luciferase reporter was used 
and the POU5F1-3′-UTR-miR-335 reporter plasmid with 
the miR-335 mimic or its control were co-transfected 
into HEK293 cells. The relative luciferase activity was 
significantly decreased in a dose-dependent manner in 
HEK293 cells after treatment with pre-miR-335 (Fig. 3b). 
In addition, the effect of the transfected oligoribonucleo-
tides diminished gradually. There was no obvious differ-
ence between the transfected and control group 2 weeks 
after transfection (Fig. 3c). Together, these results showed 
that miR-335 suppressed expression of transcripts con-
taining a miR-335-binding site. To demonstrate whether 
miR-335 inhibited POU5F1 protein expression, all three 
cell lines with pre-miR-335, anti-miR-335 and their nega-
tive controls were transfected for 24  h. We tested the 
Fig. 2 Downregulation of miR-335 enhanced osteosarcoma stem cell-like characteristics. a miR-335 antagonist increased CD117/Stro-1 double 
positive ratio in all three cell lines. b The ability of cells treated with anti-miR-335 to form sarcosphere was higher compared with pre-miR-335 and 
negative control cells. c Transwell invasion assay demonstrated that anti-miR-335 promoted cell invasion while pre-miR-335 inhibited it. All experi-
ments were carried out at least triplicates and the data were presented as the mean ± SD. Student t test was performed to evaluate the difference. 
*P < 0.05; **P < 0.01
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expression of POU5F1 in mRNA level and protein lev-
els. Using qRT-PCR, there was no significant decrease 
or increase in the mRNA level of POU5F1 by qRT-PCR 
when compared with negative controls (Fig. 3d). In con-
trast, POU5F1 protein levels decreased after overexpres-
sion of miR-335 on day 7. It also significantly increased 
after knockdown of endogenous miR-335. These changes 
disappeared on day 14, which was probably due to the 
degradation of transfected oligoribonucleotides (Fig. 3e). 
Altogether, these results suggested that miR-335 poten-
tially repressed only the protein expression of POU5F1.
miR‑335 decreased the in vivo tumor formation 
by targeting CSCs
CSCs are thought to be resistant to traditional chemo-
therapy. To examine whether miR-335 affected the 
survival to current treatments, we used cisplatin. This 
compound, which is one of the most widely used rea-
gents for osteosarcoma chemotherapy, was used to test 
the sensitivity of different osteosarcoma cells. We found 
that pre-miR-335 treatment enhanced the sensitivity 
in all three cell lines, whereas anti-miR-335 group pro-
moted chemoresistance (Fig.  4a). We then determined 
the effect of pre-miR-335 on in  vivo tumor formation. 
The mice were treated with pre-miR-335 and cisplatin, 
alone or in combination. On the sixth week, the tumors 
in the control mice were ~1 cm3, and pre-miR-335 alone 
did not alter the tumor growth. While cisplatin showed 
strong inhibitory effect on in  vivo tumor formation, 
its combination with pre-miR-335 further reduced the 
tumor size (Fig.  4b). To investigate whether miR-335 
targeted cancer stem cells in vivo, xenografts from each 
Fig. 3 miR-335 negatively regulated POU5F1 gene expression. a Bioinformatics study indicated that miR-335 was partially complementary to the 
3′-UTR of POU5F1 mRNA. b Different doses of pre-miR-335 were co-transfected with the specific pMIR-REPORT construct into HEK293 cells. Lucif-
erase activities were measured and normalized to the phRL-TK activities. c The effect of pre-miR-335 gradually diminished in 2 weeks. d Osteosarco-
mas cells were transfected with pre-miR-335, anti-miR-335 or their control respectively. After induction for 7 and 14 days, the cells were harvested 
for measurement of POU5F1 mRNA using qRT-PCR and e the protein expression using Western blot. Untreated cells was set as control, and β-actin 
acts as an internal control. All experiments were carried out at least triplicates and the data were presented as the mean ± SD. Student t test was 
performed to evaluate the difference. *P < 0.05; **P < 0.01
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group were obtained and assayed for their sphere forma-
tion efficiency. Cisplatin alone increased the capacity to 
form spheres. Although miR-335 treatment alone did 
not affect the sphere formation capacity, it decreased the 
sphere formation induced by cisplatin (Fig. 4c). Together, 
these results suggested that miR-335 targeted CSCs in a 
synergistic manner with cisplatin, to inhibit growth of 
osteosarcoma.
Discussion
Accumulating evidence has indicated that miRNAs act 
as key regulators of cell proliferation, differentiation 
and apoptosis [13]. MicroRNAs have been reported to 
play roles in the maintenance and regulation of normal 
and malignant stem cells [14]. Our results showed that 
miR-335 negatively regulated osteosarcoma stem cell-
like properties. First, we showed that the expression 
of miR-335 in osteosarcoma stem cells was lower than 
their differentiated counterparts. Second, cells express-
ing miR-335 possessed decreased stem cell-like proper-
ties compared with miR-335 low cells. Third, the miR-335 
antagonist promoted stem cell-like properties, whereas 
miR-335 expression showed the opposite effect. Fourth, 
we showed that pre-miR-335 treatment reduced tumor 
cell invasion and resistance, whereas anti-miR-335 pro-
moted tumor cell invasion and resistance. Fifth, we 
showed that miR-335 decreased the stem cell-like prop-
erties induced by cisplatin as assessed by the sphere for-
mation efficiency.
Osteosarcoma is thought to derive from mesenchymal 
stem cells (MSCs) [15]. miR-335 has been reported to 
induce cell proliferation, migration and differentiation in 
human MSCs [16]. Previous studies have also reported 
that miR-335 is downregulated in osteosarcomas [10, 17]. 
However, the status of miR-335 in osteosarcoma stem 
cells remains to be elucidated. miR-335 was shown to be 
downregulated in breast cancer stem cells and to inhibit 
CSC growth [18]. In the present study, three different 
methods were used to isolate osteosarcoma stem cells, 
and the expression of miR-335 was obviously down-regu-
lated in osteosarcoma stem cells. Additionally, functional 
experiments showed that downregulation of miR-335 
promoted osteosarcoma cells stem cell-like properties. 
These results were consistent with those of Schoeftner’s 
study, which showed that miR-335 controlled the Oct4-
pRb axis and integrated stem cell self-renewal and cell 
cycle control [19].
Previous studies have reported that POU5F1 plays an 
extremely important role in maintaining the cancer stem 
cell fate of osteosarcoma [20]. Characterizing mecha-
nism of POU5F1 regulation is therefore of vital inter-
est. In the present study, we showed that POU5F1 gene 
expression was negatively regulated by miR-335. The 
Target Scan software [21] predicted that the POU5F1 
3′-UTR was incompletely bound to miR-335, which 
means that it could repress POU5F1 expression by post-
translational regulation. Consistent with this possibility, 
when we fused the miRNAs regulatory elements (MREs) 
Fig. 4 miR-335 decreased in vivo tumor formation by targeting CSCs. a Anti-miR-335 treatment promoted chemoresistance while pre-miR-335 
enhanced sensitivity in all three cell lines. b Combination of cisplatin and pre-miR-335 orchestrated to reduce the tumor volume. c Pre-miR-335 
treatment brought down the sarcosphere formation ability induced by cisplatin. All experiments were carried out at least triplicates and the data 
were presented as the mean ± SD. Student t test was performed to evaluate the difference. *P < 0.05; **P < 0.01
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from the POU5F1 3′-UTR to luciferase, the luciferase 
reporter analysis showed that exogenous pre-miR-335 
and anti-miR-335 regulated the activity, and that sup-
pression occurred in a dose-dependent manner. We fur-
ther observed that POU5F1 was negatively regulated by 
miR-335 merely at the protein level through gain- or loss- 
of function studies. These results further confirmed that 
miR-335 repressed POU5F1 expression via imperfect 
complementation to the POU5F1 mRNA 3′-UTR.
CSCs possess intrinsic chemoresistance. The underly-
ing mechanisms include higher levels of the ABC trans-
porter and anti-apoptosis genes, efficient DNA repair, 
and detoxification by aldehyde dehydrogenase. In addi-
tion, CSCs express EMT markers suggesting that they are 
able to migrate [22, 23]. Consistent with these results, our 
studies showed that miR-335 significantly decreased drug 
resistance compared with the anti-miR-335 group and 
with the control group. Accordingly, the present study 
showed that miR-335 significantly inhibited the invasive 
potential of metastasizing cells.
CSC-targeted therapy is a promising procedure to treat 
tumor cells. We therefore investigated whether miR-335 
could selectively inhibit CSCs. Cisplatin alone increased 
the capacity to form tumor spheres in a osteosarcoma 
xenograft model, which was consistent with our previ-
ous results that conventional chemotherapy enriched for 
CSCs [11]. However, miR-335 worked together with cis-
platin in shrinking the tumor size, as well as decreasing 
the sphere formation capacity induced by cisplatin. These 
results suggested that miR335 could be an effective agent 
to eradicate CSCs.
Nonetheless, there remain some limitations in the cur-
rent study. Firstly, we did not provide clinical relevance 
in our study due to the scarcity of osteosarcoma stem 
cell in human samples. Testing the inhibitory effect of 
pre-miR-335 on patient-derived xenograft could thus 
provide more clinical importance. Secondly, it is of great 
interest to investigate the role of miR-335 in other malig-
nant bone tumor such as Ewing sarcoma and chondro-
sarcoma. Thirdly, there are plenty of genes targeted by 
miR-335, it is unknown whether genes except POU5F1 
also participate in regulating osteosarcoma stem cells. 
Finally, we used oligoribonucleotides transfection to reg-
ulate miR-335 expression, however, the effect diminished 
gradually, pre- or anti-miR-335 inducible stable cell lines 
could provide stronger evidence and further support to 
our findings.
Conclusions
Taken together, our results for the first time showed the 
relationship between miR-335 and POU5F1 in osteosar-
coma stem cells. Aside from the above limitations, these 
findings will characterize the underlying mechanisms 
of osteosarcoma and may facilitate the development of 
novel therapeutic strategies for clinical application.
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